RESEARCH

Open Access



David Dillon¹, Cavin Ward-Caviness¹, Abhijit V. Kshirsagar², Joshua Moyer¹, Joel Schwartz³, Qian Di⁴ and Anne Weaver^{1*}

Abstract

Background Chronic kidney disease (CKD) affects more than 38 million people in the United States, predominantly those over 65 years of age. While CKD etiology is complex, recent research suggests associations with environmental exposures.

Methods Our primary objective is to examine creatinine-based estimated glomerular filtration rate (eGFR_{cr}) and diagnosis of CKD and potential associations with fine particulate matter (PM_{2.5}), ozone (O₃), and nitrogen dioxide (NO₂) using a random sample of North Carolina electronic healthcare records (EHRs) from 2004 to 2016. We estimated eGFR_{cr} using the serum creatinine-based 2021 CKD-EPI equation. PM_{2.5} and NO₂ data come from a hybrid model using 1 km² grids and O₃ data from 12 km² CMAQ grids. Exposure concentrations were 1-year averages. We used linear mixed models to estimate eGFR_{cr} per IQR increase of pollutants. We used multiple logistic regression to estimate associations between pollutants and first appearance of CKD. We adjusted for patient sex, race, age, comorbidities, temporality, and 2010 census block group variables.

Results We found 44,872 serum creatinine measurements among 7,722 patients. An IQR increase in PM2.5 was associated with a 1.63 mL/min/1.73m² (95% CI: -1.96, -1.31) reduction in eGFRcr, with O_3 and NO_2 showing positive associations. There were 1,015 patients identified with CKD through e-phenotyping and ICD codes. None of the environmental exposures were positively associated with a first-time measure of eGFR_{cr} < 60 mL/min/1.73m². NO₂ was inversely associated with a first-time diagnosis of CKD with aOR of 0.77 (95% CI: 0.66, 0.90).

Conclusions One-year average $PM_{2.5}$ was associated with reduced $eGFR_{cr}$, while O_3 and NO_2 were inversely associated. Neither $PM_{2.5}$ or O_3 were associated with a first-time identification of CKD, NO_2 was inversely associated. We recommend future research examining the relationship between air pollution and impaired renal function.

Keywords Chronic kidney disease, Air pollution, Fine particulate matter, Ozone, Nitrogen dioxide, Electronic healthcare records

*Correspondence: Anne Weaver Weaver.anne@epa.gov Full list of author information is available at the end of the article



This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons/jucenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/ zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Chronic kidney disease (CKD) is a prevalent and growing health concern. Globally, CKD resulted in 1.2 million premature deaths in 2017, with an estimated prevalence of 697.5 million [1, 2]. Annual mortality is expected to increase 2.2–4.0 million by 2040 [2]. More than 38 million people in the United States live with CKD, most of whom are over the age of 65 [3, 4]. Following worldwide trends, the prevalence in the US is expected to increase in the coming decades; for those over 65 years of age, the prevalence is expected to increase by 37.8% by 2030. Older adults often experience higher levels of difficulty with both the successful management of CKD and, once the disease has progressed to end-stage kidney disease (ESKD), access to the resources necessary for kidney transplantation [5].

CKD is broadly defined by the presence of an estimated glomerular filtration rate (eGFR) of less than 60 mL/min per 1.73 m², markers of kidney damage such as albuminuria or hematuria, or both for a duration of > = 90 days, or the need for kidney replacement therapy [6]. Even a moderate decrease (eGFR of 59 to 30 mL/min per 1.73 m²) in kidney function increases the risk of hospitalization [7]. There are five stages of CKD, with stage 1 being the mildest and stage 5 indicated either severe impairment (eGFR < 15 mL/min per 1.73 m²) or kidney failure. Given the relatively mild symptoms of mild to moderate decreased kidney function, most individuals are not aware when they are in the first few stages of CKD. Prevalence of early CKD appears to be higher in females, but males progress more quickly through the disease stages and have a higher risk of mortality [8]. While standardized mortality rates for other non-communicable diseases such as cancer and cardiovascular disease have declined, CKD has not seen the same substantial decrease [9].

Most cases of CKD are caused by diabetes, hypertension, or a combination of both conditions, while other less common causes include primary glomerulonephritis, chronic tubulointerstitial nephritis, hereditary disease, secondary glomerulonephritis or vasculitis, etc. [10]. These issues are the manifestation of a combination of genetic, behavior, and environmental factors [11]. The mechanisms by which these diseases damage the kidneys over time include, but are not limited to, systemic/intraglomerular hypertension, glomerular hypertrophy, precipitation of intrarenal calcium phosphate, inflammation, and altered metabolism [10]. This chronic, consistent damage changes the overall architecture of the kidney, leading to scarring, and reduces their ability to function normally.

Recent research suggests environmental exposures as potential factors associated with the onset and progression of CKD in addition to these other factors [12]. Long-term exposure to air pollutants, specifically coarse particulate matter (PM_{10}), fine particulate matter ($PM_{2.5}$), and nitrogen dioxide (NO_2), show a mixed, but overall, consistent relationship with low kidney function [13, 14]. It is possible that there is translocation of ultrafine particles directly into the bloodstream, oxidative stress responses, or changes in the ratios and total number of immune cells [15, 16]. Ozone (O_3) may impact the kidneys as inhalation induces immunosuppressive and metabolic responses in the kidneys, heart, and liver [17]. Animal models suggest that inhalation of O_3 alters gene expression in pathways involving inflammatory signaling, antioxidation, and endothelial function [18]. However, few studies have examined the effect of O_3 on kidney disease in humans.

Our primary objective is to examine if airborne exposure to $PM_{2.5}$, O_3 , or NO_2 is associated with (1) reduced renal function as measured by serum creatinine estimated eGFR_{cr} or (2) a diagnosis of CKD in a random sample of patients from the University of North Carolina Healthcare System (UNCHCS).

Methods

Study population

We defined the sampling frame for this study to include patients with available electronic health records (EHRs) containing information on kidney health. Specifically, we include those with available serum creatinine laboratory test results and ICD codes relevant to CKD (available in Supplemental Table 1). We then separate this population into two distinct groups. The first group consists of all individuals with reported lab values for serum creatinine. We will use this group to analyze associations between air pollution and eGFR_{cr} continuously. The second group is restricted to patients with two measures of eGFR_{cr} < 60 mL/min per 1.73 m² > 90 days apart and/or an ICD code indicating a physician diagnosis of CKD III-V. This group we consider as a positive case for CKD. These positive cases will be matched with controls for analysis.

To accomplish this, we utilize data from EHRs in the in Environmental Protection Agency's Clinical and Archived Records Research for Environmental Studies (EPA CARES) [19, 20]. Our sampling frame from the EPA CARES population is a random sample of 19,989 individuals (504,406 unique visits), who were seen at a UNCHCS affiliated hospital or clinic from January 1st, 2004, to December 31st, 2016. Any participants with implausible demographic information (e.g., older than 110 years, BMI above 50, etc.) were removed prior to any analysis as it is likely these values were introduced during errors in entering information in electronic health records. Additionally, we removed any individuals who did not reside in North Carolina (n=403). For both groups (continuous outcome and binary), we linked the 1-year average $PM_{2.5}$, O_3 , and NO_2 prior to the date of the (group 1) serum creatinine laboratory tests or (group 2) the second eGFR_{cr} value < 60 mL/min per 1.73 m² or ICD code, whichever occurs earliest.

Assessment of renal function

For the eGFR analyses, we use serum creatinine levels to assess kidney function as our first outcome. We estimated $eGFR_{cr}$ using the 2021 CKD-EPI equation for serum creatinine:

using the 'MatchIt' package in RStudio. This package allowed for matching cases and controls based on designated input variables to produce more robust results with less sensitivity to assumptions. We matched according to propensity scores based on diagnosis date, age, race, and sex. For controls, who do not have a diagnosis date, we match on the closest hospital visit (Supplementary Fig. 2). We matched on the 'optimal' controls using the propensity score generating by matching variables. To ensure that we were not selecting matches from different geographic regions of the state, potentially introducing

 $eGFR_{cr} = 142 \times min(S_{cr}/\kappa, 1)^{\alpha} \times max(S_{cr}/\kappa, 1)^{-1.200} \times 0.9938^{Age} \times 1.012$ [if female]

This equation was updated in 2021 to no longer include race in estimates of $eGFR_{cr}$. Here, Scr is serum creatinine in mg/dL, κ is 0.7 for females and 0.9 for males, α is -0.241 for females and -0.302 for males, the min and max represent the minimum or maximum of the specified measurement or 1 [21]. We used the Tukey method to remove outliers, eliminating serum creatinine values more than 1.5 standard deviations above Q3 or those 1.5 standard deviations below Q1 before we calculate eGFR_{cr} [22]. Information on UACR and serum cystatin C were not included in this analysis as they were not available in the data. The analyses focused on eGFR_{cr} as a continuous outcome includes all recorded measures. Individuals may be included multiple times in the same dataset.

For our second outcome of interest, we designate an e-phenotype using similar methods described in previous research focused on kidney health utilizing EHRs [23, 24]. We consider a positive case of CKD stage III-V if a patient presents with two $eGFR_{cr}$ measures < 60 mL/ min per 1.73 m² greater than 90 days apart or has an ICD code indicating physician diagnosis. If patient data contains both types of diagnoses, we take the earliest diagnostic date. If a patient only has eGFR_{cr} measures, we take the second measure as the diagnostic date. ICD-9 codes include 585.3 - 585.6 and ICD-10 codes include N-18.3 - N18.6. We use this method as many people living with CKD are unknowingly living with CKD and may not be diagnosed by a physician. Using similar methods, Paik et al. 2021 achieved positive predictive values > 80% [23]. One-year annual air pollutant averages for the preceding 365 days are linked to the exact serum creatinine laboratory date as exposures.

Matching identified CKD cases and controls

For our CKD analyses, to ensure that our sampling was robust against bias, we matched each case to four controls (1:4) who were never diagnosed or identified as having CKD by e-phenotyping. We performed this matching confounding, we compared cases and control percentages taken from the eight climate divisions of the state (see Supplementary information) [25]. This matching was only done for patients with identified CKD. We then calculate differences in dates between cases and controls to ensure that we are sampling from similar time frames.

Exposure assessment

For $PM_{2.5}$ and NO_2 data, we used an ensemble model constructed by Di et al. that incorporates satellite aerosol measures, land-use regression, chemical transport models, and meteorological data [26]. This model incorporates three machine learning algorithms that predict pollutant concentrations in 1×1 km grids for the entirety of the contiguous Unites States. This model has been cross validated with an R² of 0.89 (for the US Middle Atlantic Region) and shows accurate performance up to concentrations of approximately 60 μ g/m³ or less [26]. The CARES patient data has the primary addresses of patients which we link to the appropriate 1×1 km grid. Where primary addresses were not successfully geocoded, we matched patients to the 1×1 km grid cell of the centroid of their primary residence ZIP code. O₃ data come from the 12 km² Community Multiscale Air Quality Modeling System (CMAQ) model; specifically, we use averaged 8-h maximum concentrations for O₃ and averaged 24-h for NO_2 [27]. CMAQ utilizes hourly measured pollutant data along with meteorological information to estimate pollutant concentrations at the census tract level. For all three pollutants, we estimate annual averages for all included patients.

Covariates

We chose covariates based on previously published research examining associations between air pollution and renal function [28]. We include individual-level sociodemographic information of age, race (Caucasian, African American, other), and sex as factors. We created

the 'other' race category as there were too few patients of other racial backgrounds that were not Caucasian or African American to include separately in models. Clinical diagnosis of both diabetes and hypertension were included in descriptive statistics based on ICD-9 and ICD-10 codes (250.x and E11.x for diabetes and 401.9 and I10 for primary hypertension) (full list of ICD codes available in Supplementary information). However, these were excluded from models as they are both likely mediators of kidney function and onset of CKD. Event-specific instances of these diseases (e.g., pregnancy induced hypertension) were not included in this analysis. We adjusted for the following 2010 census/2013 5-year ACS variables at the block group level: income, percent older housing (built before 1979), percent living in poverty, urbanicity, and percent of the population on public assistance, all as continuous covariates. Education (percent with a bachelor's degree or higher) and median price of housing were included in descriptive statistics but excluded from final models due to high collinearity (r > |0.7|) with income. Lastly, climate zones (identified from climatechange.nc.gov) were included as regional adjustment for unmeasured factors that differ between regions in North Carolina as a factor in our models. Smoking status and body mass index (BMI) were not included in the main analyses as they were not recorded for a large portion of patients and only reported as secondary analyses.

Statistical analyses

We analyzed associations between eGFR_{cr} and air pollutants using linear mixed models, presenting unadjusted and fully adjusted models, with a random intercept for patient ID. We first calculated descriptive statistics for patients. Following this we calculated Pearson correlations between PM2,5, O3, and NO2 to examine the relationship between the exposures of interest. To make exposures more comparable we then calculate interguartile range (IQR) for use in the models. We controlled for the continuous census block group covariates including average income, percent older housing (built before 1979), percent living in poverty, urbanicity, and percent of the population on public assistance. Demographic covariates included age, sex, and race. As patients were more likely to be sampled from geographic regions closer to hospitals near the flagship UNC Chapel Hill hospital, we control for the climate zones (as identified by the NC Climate Division, map available in Supplementary information) in North Carolina. There are eight climate zones in North Carolina, however due to too few observations we only include zones 3-8 in our analyses (n = 15 patients removed).

We calculated eGFR_{cr} as a continuous outcome along with serum creatinine pre-transformation as a secondary outcome. 1-year average concentrations for PM_{2.5}, O_3 , and NO_2 were matched to the date the laboratory test for serum creatinine was completed. We then calculated IQRs for each pollutant during the 1-year period to make them more comparable. Our fully adjusted models included age and race, census block group information (median income, % older housing, % poverty, urbanicity, % on public assistance), geographic region, and exposures (PM2.5, O3, and NO2) along with unrestricted natural cubic spline adjustment for long-term temporal variations with the number of splines based on the Aikake information criteria. We present only the results of multipollutant models, information on single pollutant models is available in Supplementary table S3.

We conducted unconditional multiple logistic regression to estimate odds ratios between first indication date of CKD and air quality for 1-year prior to diagnosis comparing our cases and controls (results of conditional are available in Table S4) [29]. The census block group, demographic, and comorbidity covariates included in our multiple logistic regression models were the same as those included in the linear mixed models. All analyses and visualizations were completed using SAS software version 9.4 and RStudio 4.0.3 [30, 31]. In RStudio we used the package 'matchit' for matching cases and controls for our multiple logistic regression models [32].

Sensitivity analysis

Body mass index (BMI) and smoking status were not reported for all patients in the random sample and were used in secondary analyses to ensure that their inclusion did not alter the linear mixed models described previously. BMI is available for n = 18,639 (n = 4,834 patients) serum creatinine lab measures and smoking status is available for n = 30,913 (n = 5,532 patients). Smoking status was separated into five categories including current, current/former, former, never/former, and never. Smoking status was attached to the same day serum creatinine tests were taken, or if it was not assessed that day, then the nearest prior date where smoking status was available. We ran two additional fully adjusted models with the same covariates in addition to BMI (continuous) and smoking status. For both analyses including BMI and smoking status, we calculate associations with and without the additional confounder to ensure that differences seen are not driven by underlying characteristics of the new sampling frames. We ran the fully adjusted models comparing cases of CKD to the entire random sample (available in Supplementary data). For patients without CKD, we ran two models, attaching an exposure date as both first appearance in the hospital system and median

visit to ensure that results were consistent at different time points. Lastly, we include only those with streetlevel geocoded addresses (some patients were coded at zip code) to ensure the most accurate assignment of exposures.

Stratified analysis

We also stratified by individuals who were exposed to 1-year PM_{2.5} averages $\geq 12 \ \mu g/m^3$ and those $< 12 \ \mu g/m^3$ [33]. This threshold was chosen based on current (2022) National Ambient Air Quality Standards (NAAQS) primary standard for PM_{2.5}. To estimate associations of air pollution on patients with low functioning kidneys we stratify by those patients with a measure of an eGFR_{cr} $< 60 \ mL/min/1.73m^2$.

Results

There were N=7,722 patients with available serum creatinine to calculate $eGFR_{cr}$ and exposure data linked to primary address. Within this group there were N=44,486 serum creatinine tests available during our study period (Tables 1 and 2). BMI is available for n=18,639 (n=4,834 patients) serum creatinine lab measures and smoking status is available for n=30,913 (n=5,532 patients). Patients with serum creatinine measures average 53.6 (SD: 17.9) years of age, are majority female (58.2%), and majority Caucasian (64.7%). The prevalence of diabetes and hypertension in this group were 25.6% and 57.6% respectively. This group was, on average, exposed to 1-year median concentrations at 9.52 (IQR: 1.57) of PM_{2.5} µg/m³, 39.7 ppb O₃ (IQR: 3.21), and 12.8 ppb NO₂ (IQR: 8.68).

We included N=4,952 patients in our case-control sample that captures all patients identified with CKD and corresponding controls. Within this group, we identified 1,015 patients with severely limited kidney function (ICD code or two eGFR_{cr} < 60 mL/min per 1.73 m²), and 3,937 non-CKD patients as controls. Those with CKD were more likely to be diagnosed with diabetes and/or hypertension. Patients with CKD had patterns of lower block group SES status as indicated by higher percent poverty, lower average income, and median house value. However, there were few differences between block-level percentage poverty or those on public assistance. Those diagnosed with CKD were exposed to lower 1-year median concentrations of $PM_{2.5}$ (11.2 µg/m³ IQR: 3.64), O₃ (41.4 ppb IQR: 3.39), and NO₂ (14.1 ppb IQR: 10.8) when compared to the non-CKD patients median PM_{25} 11.3 µg/m³ (IQR: 3.33), O₃ 41.7 ppb (IQR: 3.35), and NO₂ 15.4 ppb (IQR: 10.8). Standardized mean difference (SMD) in propensity scores for diagnostic date vs. hospital visit dates between cases and controls were 0.048 on average (full table of summary balances for matched data available in Supplementary table S2). All our SMDs between cases and control were less than 0.1, indicating adequate balancing, with the exception of African American patients (SMD=0.11) and Other Race (SMD=-0.11) and may limit the interpretability of the results in these cases.

Results from multiple linear regression models estimate an association between IQR increases in $PM_{2.5}$ and a decline in eGFR_{cr} (-1.63 mL/min/1.73m², 95% CI: -1.96, -1.31). The results for O₃ and NO₂ are 0.28 mL/min/1.73m² (95% CI: 0.00 0.55) and 0.48 (95% CI: 0.03, 0.92), respectively. Likewise, there was a positive association between PM_{2.5} and serum creatinine (0.052 mg/dL, 95% CI: 0.031, 0.073). We observed an inverse association between O₃ and serum creatinine and no association between NO₂ and serum creatinine, with estimates of -0.030 (95% CI: -0.048, -0.012) and 0.024 (95% CI: -0.005, 0.052), respectively (Table 3 and Fig. 1).

In the fully adjusted logistic regression model, neither $PM_{2.5}$ or O_3 were associated with CKD with aORs of 1.04 (95% CI: 0.88, 1.22) and 0.89 (95% CI: 0.78, 1.01) respectively. NO₂ was inversely associated with CKD with an aOR of 0.79 (95% CI: 0.68, 0.92 (Fig. 2).

For patients with an $eGFR_{cr} \ge 60 \text{ mL/min/1.73 m}^2$ the association between IQR increases in PM2.5 and eGFRcr was -1.06 (95% CI: -1.34, -0.77). For those with impaired renal function, $< 60 \text{ mL/min}/1.73 \text{ m}^2$, the association was weaker, -0.51 (95% CI: -0.90, -0.13). For those exposed to less than 12 μ g/m³ of PM_{2.5} the associated with eGFR_{cr} were weaker, while at concentrations above 12 μ g/m³ the associations were stronger at -0.78 (95% CI: -1.13, -0.43) and -2.58 (95% CI: -3.82, -1.33). When BMI was included in our fully adjusted model, the association of PM_{2.5} with eGFR_{cr} was -0.74 (95% CI: -1.21, -0.28). In the second model with smoking status included, the association of PM_{2.5} with eGFR_{cr} were -1.00 (95% CI: -1.30, -0.70) (note, we did not include both BMI and smoking status in the same model). To ensure that our models including smoking status or BMI cohorts were not altering our general results we ran these two groups without the additional covariates. The results of our models without including the confounder were -1.01 (95% CI: -1.31, -0.71) for smoking status and -0.74 (95% CI: -1.20, -0.28) for BMI.

 $PM_{2.5}$ was more strongly associated with reduced renal function in African American patients (-2.40, 95% CI: -3.00, -1.79). While Caucasian patients (-1.27, 95% CI: -1.66, -0.88) showed weaker association between $PM_{2.5}$ and renal function than the main model. The association between $PM_{2.5}$ and eGFR_{cr} was -1.85 (95% CI: -2.32, -1.39 for men and -1.31 (95% CI: -1.76, -0.87) for women. After restricting to only patients with street-level geocoded addresses, there were 6,710 patients and 40,461 unique tests for serum creatinine left in our sample. For those with street-level geocoded addresses the association between $PM_{2.5}$ and eGFR_{cr} was similar as for

Patients with eGFR _{cr} $N = 7,722$			
Characteristics	n (%)		
Female	4,498 (58.2)		
Male	3,227 (41.8)		
Caucasian	5,000 (64.7)		
African American	2,128 (27.6)		
Other	596 (7.72)		
Diabetes	1,976 (25.6)		
Hypertension	4,453 (57.6)		
Mean (SD or %)			
Age	53.6 (17.9)		
Education	36.3 (24.8)		
Older housing	40.6 (23.3)		
Income (USD)	58,005.9 (29,470.8)		
Median house value (USD)	203,462.7 (119,096.6)		
Poverty (%)	16.6 (13.8)		
Public assistance (%)	1.99 (3.05)		
Urbanicity	62.9 (41.8)		
Median (IQR)			
PM _{2.5} (μg/m³)	9.52 (1.57)	NO ₂ (ppb)	12.8 (8.68)
O ₃ (ppb)	39.7 (3.21)		
Patients with CKD and never-diagnosed N =	= 4,952		
	Non-CKD	CKD	Total
n (%)			
Female	2,199 (55.9)	553 (54.5)	2,752
Male	1,738 (44.2)	462 (45.5)	2,200
Caucasian	2,279 (57.9)	560 (55.2)	2,839
African American	1,419 (36.0)	415 (40.9)	1,834
Other Race	239 (6.1)	40 (3.9)	279
Diabetes	1,049 (26.6)	476 (46.9)	1,525
Hypertension	2,422 (61.5)	860 (84.7)	3,282
Mean (SD)			
Age	65.4 (16.4)	65.3 (16.4)	65.4 (16.4)
Area level covariates*			
Income	58,199.3 (27,147.3)	54,710.5 (25,511.6)	57,484.2 (26,854.7)
Poverty (%)	16.1 (12.6)	17.6 (13.9)	16.41 (12.9)
Urbanicity	66.7 (40.7)	60.9 (42.1)	65.47 (41.1)
Public assistance (%)	1.7 (2.7)	2.0 (2.9)	1.75 (2.8)
Median house value	211,306.8 (120,322.1)	197,977.3 (117,589.7)	208,574.7 (119,876.2)
Education	38.2 (25.47)	35.0 (24.8)	37.5 (25.4)
Median (IQR)			
PM _{2.5} (μg/m ³)	11.31 (3.33)	11.18 (3.64)	11.27 (3.39)
O ₃ (ppb)	41.66 (3.35)	41.41 (3.39)	41.59 (3.37)
NO ₂ (ppb)	15.44 (10.77)	14.11 (10.82)	15.10 (10.80)

Table 1 Descriptive characteristics for the subset of NC-CARES with (1) available eGFR_{cr} values and (2) cases and controls for patients diagnosed with CKD

* Data for block groups come from the 2010 US Census/2013 5-Year ACS; any category that does not sum to 100% is a result of rounding; Education is measure by percentage with a bachelor's degree or higher; older housing refers to the percentage of houses built before 1979

Table 2	Pearson	correlations	of PM _{2.5} ,	O ₃ ,	and	NO_2	for	both	the
linear mi	xed and	the multiple	logistic re	egre	ssior	mod	dels		

Linear mixed models				
	PM _{2.5}	O ₃	NO ₂	
PM _{2.5}	1.00	0.53	0.40	
O ₃	-	1.00	0.11	
NO ₂	-	-	1.00	
Multiple logistic regression models				
	PM2.5	O3	NO2	
PM _{2.5}	1.00	0.55	0.38	
O ₃	-	1.00	0.2	
NO ₂	-	-	1.00	

the entire patient group with an estimate of -1.57 (95% CI: -1.91, -1.23). For this group both O_3 and NO_2 were not associated with eGFR_{cr} (available in Supplementary information).

Discussion

In this study, we examined the relationship between 1-year average $PM_{2.5}$, O_3 , and NO_2 concentrations with kidney function as measured by $eGFR_{cr}$ and first indication of CKD. Only increases in 1-year mean concentrations of $PM_{2.5}$ were associated with a decrease in $eGFR_{cr}$ while both O_3 and NO_2 were not associated. The trends seen for $eGFR_{cr}$ were similar to the associations between the three air pollutants and serum creatinine prior to

Table 3 Results from mixed linear models & logistic regression of 1-year $PM_{2.5}$, O_3 , NO_2 and kidney function among a random sample of NC CARES serum creatinine laboratory results (N = 44,486)

	IQR 1-year PM _{2.5} (µg/m ³)	IQR 1-year O ₃ (ppb)	IQR 1-year NO ₂ (ppb)
eGFR _{cr} (mL/min/1.73m	²) β (95% CI)		
Model 1	-1.44 (-1.72, -1.15) -0.32 (-0.56, -0.08)		0.80 (0.34, 1.25)
Model 2	-1.63 (-1.96, -1.31)	0.28 (0.00 0.55)	0.48 (0.03, 0.92)
CKD aOR (95% CI)			
Model 1	0.87 (0.73, 1.05)	0.91 (0.84, 1.00)	0.73 (0.66, 0.80)
Model 2	1.04 (0.88, 1.22)	0.89 (0.78, 1.01)	0.79 (0.68, 0.92)

^a Model 1 Estimate with only random intercepts for patients and spline adjustment for temporal variation

^b Model 2 fully adjusted linear mixed model estimate for temporal variations, age, sex, race, comorbidities, and census block group

 c IQR for exposures in our eGFRcr analysis are: PM $_{2.5}$ – 1.43 $\mu g/m^3;$ O $_3$ – 2.81 ppb; NO $_2$ – 8.49 ppb

 d IQR for exposures in our CKD analysis are: PM $_{2.5}$ – 3.39 $\mu g/m^3;$ O $_3$ – 3.36 ppb; NO $_2$ – 10.45 ppb



Fig. 1 Results of linear mixed models examining the associations of air pollutants with eGFR_{cr}



Fig. 2 Results of logistic regression models examining the associations of air pollutants with CKD

transformation. For first indication of CKD, we observe null associations between 1-year concentrations of $PM_{2.5}$ and O_3 and inverse association with NO_2 .

These results support other epidemiologic studies that report an inverse association between IQR increases in PM_{2.5} and eGFR_{cr} [34–36]. Likewise, observed positive associations between O3 and eGFRcr has been reported in other studies [37]. Weaver et al. report a lack of association between long term O₃ exposure and decreased eGFR in a manner consistent to these results [28]. These findings contrast to prior studies that find associations between NO₂ and kidney function as measured by both eGFR and risk of CKD/ESKD [38, 39]. Li et al., 2021 examined a smaller population (n=169) of older adults, while Liang et al. 2021 reported the results of a large (n=47,086) nationally representative sample. It is possible that there is a relationship between NO₂ and decreased renal function, but 1-year concentrations are not long enough to capture the relationship. NO_2 is very source dependent, and future work may want to investigate those living near roadways, as this is a major source of NOx exposure in the United States. In a nationwide cross-sectional study in China, Liang et al. show an increased risk of developing CKD with longer term exposure to higher concentrations of NO₂, with the risk being greatest at 5-years of exposure (for example Liang et al. and Li et al. report median concentrations for NO₂ at approximately 24 and 23 ppb respectively) [38]. Though, generally, levels of air pollution in China are higher than the US/Europe, so there may be dose-dependent responses we do not see in this study, particularly as these two studies reported higher concentrations of NO₂.

Despite higher concentrations of PM_{2.5} being associated with lower $\mathrm{eGFR}_{\mathrm{cr}}$, we do not see a similar relationship between PM2.5 and first-time indication of CKD. Inverse associations were seen with O₃ and NO₂ with incident CKD. Prior studies, such as Yang et al., 2022 have reported positive association between O₃ and the prevalence of CKD in a nationwide Chinese study [37]. Similar findings in other studies have found no associations between O3 and incidence of CKD, suggesting that more studies are needed that reflect impacts on the general population [40]. O₃ is relatively less studied than other criteria air pollutants in association with CKD [41]. It is notable that the majority of studies focusing on air pollution and kidney function/ disease take place in either the United States or Asia or studied a special population such as military veterans [13, 35]. As such, more research should be conducted to better understand these associations in other geographic regions, cultural and social context, climatic regions, etc.

African American patients were exposed to higher concentrations of $PM_{2.5}$ on average than both Caucasian and patients of another race. In our stratified analyses, African American patients were more likely to have lower eGFR_{cr} when compared to Caucasians. These differences in outcome by race are likely a result of social determinants of health impacting disparities in renal health [42]. The African American population in the US, relative to other ethnicities, make up a disproportionately large percentage of those with CKD [43]. It is important for future research to investigate other potential environmental, social contributors, and interactions between these to these health disparities.

We further conducted stratified analyses by PM_{2.5} concentrations, age, and limited analyses to those with streetlevel geocoded addresses. We found the associations between $PM_{2.5}$ and decreased in $eGFR_{cr}$ were decreased at concentrations < 12 μ g/m³ but increased at higher levels. This particular result needs further investigation as these findings do not directly support the growing body of evidence that even at lower concentrations (e.g., US NAAQS standards), air pollution has deleterious impacts on health [44-46]. On the impacts of age, the estimate for PM_{25} and $eGFR_{cr}$ was stronger for those < 65 years of age, with weaker associations observed for older patients. This may be a result of older patients being more likely to be on anti-hypertensive medication or medication for diabetes. After stratifying by CKD status, or those not identified with CKD, the association with O_3 is inverse. For individuals diagnosed with CKD this may be that, given the high percentage of comorbidities, the impact of air pollution may be exacerbated by directly impacting regulation of both blood sugar and pressure [47].

A limitation of this study is that the patients included in these analyses resided predominantly in central North Carolina, where the majority of UNCHCS affiliated hospitals or clinics are located. Due to relative underrepresentation our African American and Other Race patients were not matched to the level of our Caucasian patients, which could introduce bias. With address geocoding there is always the possibility of misclassification that cannot be assumed to trend towards the null. As such this study may lack generalizability to the general population. Using 1-year average air pollution concentrations does not capture the entirety of the time air pollution potentially impacted kidney health. Census block group level covariates do not necessarily capture individual SES, which ideally would have been at the individual level; there could be residual confounding by SES. Finally, it is likely that serum creatinine was measured more often for patients with suspected renal dysfunction, biasing the sample towards those with already impaired kidney function. Unexpected directionality arose concerning associations between NO₂ and kidney function in our analyses. This is likely due to additional, unmeasured confounding, dose-dependent effects, geographic proximity to roadways, etc. that were not addressed in the scope of this work. This is an area we recommend additional research be focused. Further, there is the possibility that there is the possibility that there is a time x exposure interaction that was not accounted for in this current study. Lastly there are limitations when using EHR data such as representativeness, the data available, missing or incorrectly entered measures, etc.

One of the strengths of this study is that it takes a random sample of patients visiting the North Carolina healthcare system and does not focus on a special subpopulation. This random sample has near complete clinical phenotyping and well validating air pollution modeling estimates, matched with high precision geocoding. Additionally, by utilizing e-phenotyping of CKD, we may be more accurately estimating associations between air pollution and reduced renal function as CKD is often not diagnosed until the latter stages.

In conclusion, we observed reduced renal function, as measured by $eGFR_{cr}$, with 1-year concentrations on $PM_{2.5}$, but not with O_3 or NO_2 . No exposures were associated with increased odds of CKD, while NO_2 was inversely associated. This study provides further evidence that long-term exposure to fine particulate matter is associated to reduced renal function and may contribute to adverse outcomes.

Abbreviations

BMI	Body Mass Index			
CKD	Chronic Kidney Disease			
CMAQ	Community Multiscale Air Quality Modeling System			
EHRs	Electronic Health Record			
EPA CARES	Environmental Protection Agency's Clinical and Archived			
	Records Research for Environmental Studies			
ESKD	End-Stage Kidney Disease			
eGFR	Estimated Glomerular Filtration Rate			
eGFR _{cr}	Serum Creatinine Estimated Glomerular Filtration Rate			
FIPS	Federal Information Processing System			
IQR	Interquartile range			
NAAQS	National Ambient Air Quality Standards			
NKDEP	National Kidney Disease Education Program			
NO ₂	Nitrogen dioxide			
O3	Ozone			
PM _{2.5}	Particulate matter < 2.5 μm in diameter			
Scr	Serum Creatinine			
SES	Socioeconomic Status			
UA	Urinary Albumin			
LIACR	Lirinary Albumin/creatinine ratio			

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12940-024-01080-4.

Supplementary Material 1.

Acknowledgements

We would like to acknowledge internal reviewers Kristen Rappazzo and Alison Krajewski for providing feedback during the preparation of this manuscript.

Disclaimer

This work does not necessarily represent the views or policy of the US EPA. Any mention of trade names does not constitute endorsement.

Authors' contributions

DD: conceptualization, methodology, software, formal analysis, writing, visualization. CWC: conceptualization, methodology, writing, supervision, project administration. AK: conceptualization, methodology, writing. JM: resources, data curation. JS. resources, data curation, writing QD. resources, data curation, writing. AW: conceptualization, methodology, software, writing, supervision, funding acquisition. All authors reviewed the manuscript.

Funding

All funding for this study was provided by the U.S. Environmental Protection Agency. The funder had no role in the study design, data collection, analysis, interpretation, or manuscript writing. This research was supported, in part, by appointments to the Research Participation Program for the U.S. Environmental Protection Agency, Office of Research and Development, administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the U.S. Department of Energy and Environmental Protection Agency. This work was performed as part of normal duties by EPA employees and contractors.

Availability of data and materials

The data for this study contain identifiable information and cannot be shared. More information regarding data access and requests for access may be found here https://tracs.unc.edu/. Analytic code used in this publication are available from the authors upon reasonable request.

Declarations

Ethics approval and consent to participate

This research was approved by the University of North Carolina at Chapel Hill, IRB # 17–0150.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Center for Public Health and Environmental Assessment, United States Environmental Protection Agency, Research Triangle Park, NC, USA. ²Division of Nephrology and Hypertension, University of North Carolina School of Medicine, Chapel Hill, NC, USA. ³T.H. Chan School of Public Health, Harvard University, Boston, MA, USA. ⁴Research Center for Public Health, School of Medicine, Tsinghua University, Beijing, China.

Received: 13 July 2023 Accepted: 5 April 2024 Published online: 23 April 2024

References

- Carney E. The impact of chronic kidney disease on global health. Nat Rev Nephrol. 2020;16:251.
- Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2020;395(10225):709–33.
- 3. Webster A, Nagler E, Morton R, Masson P. Chronic Kidney Disease. The Lancet. 2017;389:1238–52.
- Anderson S, Halter JB, Hazzard WR, Himmelfarb J, Horne FM, Kaysen GA, et al. Prediction, progression, and outcomes of chronic kidney disease in older adults. J Am Soc Nephrol. 2009;20(6):1199–209.
- Ashby VB, Kalbfleisch JD, Wolfe RA, Lin MJ, Port FK, Leichtman AB. Geographic variability in access to primary kidney transplantation in the United States, 1996–2005. Am J Transplant. 2007;7(5 Pt 2):1412–23.
- Eknoyan G, Lamiere N, Eckardt K, Kasiske B, Wheeler D, Levin A, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1):5–14.
- Schrauben SJ, Chen H[']Y, Lin E, Jepson C, Yang W, Scialla JJ, et al. Hospitalizations among adults with chronic kidney disease in the United States: A cohort study. PLoS Med. 2020;17(12): e1003470.
- Carrero JJ, Hecking M, Chesnaye N, Jager K. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol. 2018;14:151–64.
- 9. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic

analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1736–88.

- 10. Vaidya S, Aedulla N. Chronic Renal Failure: StatPearls Publishing; 2021 [Available from: https://www.ncbi.nlm.nih.gov/books/NBK535404/#:~: text=Chronic%20kidney%20disease%20(CKD)%20is%20defined%20as% 20kidney%20damage%20or,till%20stages%20IV%20and%20V.
- Obrador GT, Schultheiss UT, Kretzler M, Langham RG, Nangaku M, Pecoits-Filho R, et al. Genetic and environmental risk factors for chronic kidney disease. Kidney Int Suppl (2011). 2017;7(2):88–106.
- 12. Tsai HJ, Wu PY, Huang JC, Chen SC. Environmental Pollution and Chronic Kidney Disease. Int J Med Sci. 2021;18(5):1121–9.
- Wu MY, Lo WC, Chao CT, Wu MS, Chiang CK. Association between air pollutants and development of chronic kidney disease: A systematic review and meta-analysis. Sci Total Environ. 2020;706:135522.
- Rasking L, Vanbrabant K, Bove H, Plusquin M, De Vusser K, Roels HA, et al. Adverse Effects of fine particulate matter on human kidney functioning: a systematic review. Environ Health. 2022;21(1):24.
- Rao X, Zhong J, Brook RD, Rajagopalan S. Effect of Particulate Matter Air Pollution on Cardiovascular Oxidative Stress Pathways. Antioxid Redox Signal. 2018;28(9):797–818.
- Wold LE, Simkhovich BZ, Kleinman MT, Nordlie MA, Dow JS, Sioutas C, et al. In Vivo and In Vitro Models to Test the Hypothesis of Particle-Induced Effects on Cardiac Function and Arrhythmias. Cardiovasc Toxicol. 2006;6(1):69–78.
- 17. Xu X, Nie S, Ding H, Hou FF. Environmental pollution and kidney diseases. Nat Rev Nephrol. 2018;14(5):313–24.
- Thomson EM, Vladisavljevic D, Mohottalage S, Kumarathasan P, Vincent R. Mapping acute systemic effects of inhaled particulate matter and ozone: multiorgan gene expression and glucocorticoid activity. Toxicol Sci. 2013;135(1):169–81.
- Ward-Caviness CK, Weaver AM, Buranosky M, Pfaff ER, Neas LM, Devlin RB, et al. Associations Between Long-Term Fine Particulate Matter Exposure and Mortality in Heart Failure Patients. J Am Heart Assoc. 2020;9(6):e012517.
- Ward-Caviness CK, Danesh Yazdi M, Moyer J, Weaver AM, Cascio WE, Di Q, et al. Long-Term Exposure to Particulate Air Pollution Is Associated With 30-Day Readmissions and Hospital Visits Among Patients With Heart Failure. J Am Heart Assoc. 2021;10(10):e019430.
- Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737–49.
- Tukey WJ. Exploratory Data Analysis. Indianapolis: Addison-Wesley Publishing Company; 1977.
- Paik JM, Patorno E, Zhuo M, Bessette LG, York C, Gautam N, et al. Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data. Pharmacoepidemiol Drug Saf. 2022;31(4):467–75.
- 24. Norton JM, Ali K, Jurkovitz CT, Kiryluk K, Park M, Kawamoto K, et al. Development and Validation of a Pragmatic Electronic Phenotype for CKD. Clin J Am Soc Nephrol. 2019;14(9):1306–14.
- 25. NOAA. Location of US Climate Divisions 2022 [Available from: https://psl. noaa.gov/data/usclimdivs/data/map.html.
- 26. Di Q, Amini H, Shi L, Kloog I, Silvern R, Kelly J, et al. An ensemble-based model of PM2.5 concentration across the contiguous United States with high spatiotemporal resolution. Environ Int. 2019;130:104909.
- 27. EPA U. CMAQ: The Community Multiscale Air Quality Modeling System 2022 [updated October 14, 2022. Available from: https://www.epa.gov/cmaq.
- Weaver AM, Wang Y, Wellenius GA, Young B, Boyle LD, Hickson DA, et al. Long-term exposure to ambient air pollution and renal function in African Americans: the Jackson Heart Study. J Expo Sci Environ Epidemiol. 2019;29(4):548–56.
- Kuo CL, Duan Y, Grady J. Unconditional or Conditional Logistic Regression Model for Age-Matched Case-Control Data? Front Public Health. 2018;6:57.
- 30. RStudio Team. RStudio: Integrated Development for R. 4.0.3 ed. Boston, MA: RStudio; 2022.
- 31. SAS Institute Inc. SAS Software. 9.4 ed. Cary, NC2022.
- Ho D, Imai K, King G, Stuart EA. Matchlt: Nonparametric Preprocessing for Parametric Causal Inference. Journal of Statistical Software. 2011;42(8):1–28.

- EPA U. NAAQS Table 2022 [Available from: https://www.epa.gov/criteriaair-pollutants/naaqs-table.
- Zeng Y, Lin C, Guo C, Bo Y, Chang LY, Lau AKH, et al. Combined effects of chronic PM2.5 exposure and habitual exercise on renal function and chronic kidney disease: A longitudinal cohort study. Int J Hyg Environ Health. 2021;236.
- Bowe B, Xie Y, Li T, Yan Y, Xian H, Al-Aly Z. Particulate Matter Air Pollution and the Risk of Incident CKD and Progression to ESRD. J Am Soc Nephrol. 2018;29(1):218–30.
- Kuzma L, Malyszko J, Bachorzewska-Gajewska H, Kralisz P, Dobrzycki S. Exposure to air pollution and renal function. Sci Rep. 2021;11(1):11419.
- Yang C, Wang W, Wang Y, Liang Z, Zhang F, Chen R, et al. Ambient ozone pollution and prevalence of chronic kidney disease: A nationwide study based on the China National survey of chronic kidney disease. Chemosphere. 2022;306:135603.
- Liang Z, Wang W, Wang Y, Ma L, Liang C, Li P, et al. Urbanization, ambient air pollution, and prevalence of chronic kidney disease: A nationwide cross-sectional study. Environ Int. 2021;156:106752.
- Li A, Mei Y, Zhao M, Xu J, Li R, Zhao J, et al. Associations between air pollutant exposure and renal function: A prospective study of older adults without chronic kidney disease. Environ Pollut. 2021;277:116750.
- Hwang SY, Jeong S, Choi S, Kim DH, Kim SR, Lee G, et al. Association of Air Pollutants with Incident Chronic Kidney Disease in a Nationally Representative Cohort of Korean Adults. Int J Environ Res Public Health. 2021;18(7):3775.
- Ye JJ, Wang SS, Fang Y, Zhang XJ, Hu CY. Ambient air pollution exposure and risk of chronic kidney disease: A systematic review of the literature and meta-analysis. Environ Res. 2021;195:110867.
- 42. Hall YN. Social Determinants of Health: Addressing Unmet Needs in Nephrology. Am J Kidney Dis. 2018;72(4):582–91.
- Maraboto C, Ferdinand KC. Update on hypertension in African-Americans. Prog Cardiovasc Dis. 2020;63(1):33–9.
- 44. Kampa M, Castanas E. Human health effects of air pollution. Environ Pollut. 2008;151(2):362–7.
- 45. Al-Kindi SG, Brook RD, Biswal S, Rajagopalan S. Environmental determinants of cardiovascular disease: lessons learned from air pollution. Nat Rev Cardiol. 2020;17(10):656–72.
- Di Q, Wang Y, Zanobetti A, Wang Y, Koutrakis P, Choirat C, et al. Air Pollution and Mortality in the Medicare Population. N Engl J Med. 2017;376(26):2513–22.
- Krishnan RM, Adar SD, Szpiro AA, Jorgensen NW, Van Hee VC, Barr RG, et al. Vascular responses to long- and short-term exposure to fine particulate matter: MESA Air (Multi-Ethnic Study of Atherosclerosis and Air Pollution). J Am Coll Cardiol. 2012;60(21):2158–66.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.